Moderna (MRNA) Preferred Stock Liabilities (2017)

Moderna (MRNA) posted quarterly Preferred Stock Liabilities of $1.2 billion for Q4 2017.

Moderna (MRNA) Preferred Stock Liabilities (2017) Analysis & Trends

Moderna has reported Preferred Stock Liabilities for 1 years, with the latest figure at $1.2 billion in Q4 2017.

Preferred Stock Liabilities for Q4 2017 came in at $1.2 billion, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was $1.2 billion (changed N/A YoY), and the FY2017 annual result was $1.2 billion, changed 0.0% from the prior year.
Preferred Stock Liabilities steadied at $1.2 billion in Q4 2017.
Over five years, Preferred Stock Liabilities peaked at $1.2 billion in Q4 2017 and troughed at $1.2 billion in Q4 2017.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Moderna	25.26 Bn	20.13 Bn	52.00 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2017	1.18 Bn